News | May 28, 2021
Bharat Biotech signs MoU with GCVC for COVID Vaccine
It is expected that the drug substance would be available from August 2021 which will be supplied back to Bharat Biotech for producing COVAXIN
It is expected that the drug substance would be available from August 2021 which will be supplied back to Bharat Biotech for producing COVAXIN
The roller coaster ride during the pandemic has taken Indian pharmaceutical industry through a lot of bitter sweet experiences.
The company reported net profit for FY21 at Rs. 2,903.8 crore, lower by 23% over last year
Revenue from operations for the year ended March 31, 2021 is ?2,239 crore
The turnover of its NPNC Formulations Division (IKKT Undertaking) for FY 2020-2021 is Rs.21.33 Cr
The company has reported total income of Rs.826.40 crores for FY 2020-21
The company plans to enter the EU markets in FY22
We focused on developing the product last year but now our focus is on ramping up our manufacturing capacity
Availability of drugs is being monitored by implementing a three-pronged strategy of supply chain management, demand side management, and affordability.
This kit was developed in partnership with Gujarat-based LabCare Diagnostics. LabCare is into clinical chemistry reagents, serology tests, immuno-chromatographic tests and urine analysis strips
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
